US-based rheumatologist and IPC Councilor Arthur Kavanaugh, MD, discusses his plans to continue offering telemedicine appointments to patients after the pandemic. "Telemedicine is a new skill set that [we] providers need to learn," says Dr. Kavanaugh in this week's Stories from the Field video.

Due to COVID-19 restrictions, patients in Egypt with severe psoriasis are not getting timely access to biologic treatment. IPC Board Member Mahira Hamdy El Sayed, MSc, MD, discusses the potential fallout for Egyptians with psoriasis, post-COVID-19.

Dr. Lluís Puig provides his comments on a recent publication on the classification of the cutaneous manifestations of COVID‐19.

Catherine Smith, MD, and Savteer Mahil, MD, talk to IPC Chief Medical Officer Peter van de Kerkhof, MD, PhD, about their goals for the PsoProtect patient registry to study COVID-19 and psoriasis.

Soon after COVID-19 was declared a pandemic, the question if particular patient groups – those with immune-mediated inflammatory disease (IMID) and/or those on an immunosuppressant treatment – are at higher risk to become infected and/or are at risk for developing a more severe course of the disease.

Commentary from IPC Councilor Mark Lebwohl, MD, on a case series in NEJM on COVID-19 in immune-mediated inflammatory diseases.

Conexión, conversación, claridad: el miembro de la junta de IPC, Claudia de la Cruz, MD, ofrece consejos sobre cómo comunicarse con pacientes con psoriasis que están preocupados por COVID-19 y su salud.

Connection, conversation, clarity: IPC Director Claudia de la Cruz, MD, offers advice on communicating with psoriasis patients who are worried about COVID-19 and their health.    

ntroducing PsoProtectMe, a registry for people with psoriasis to report on their health now.

Para pacientes com psoríase diagnosticados com doença causada pelo COVID-19, o IPC recomenda que médicos interrompam ou adiem o uso de medicamentos imunossupressores. Esta recomendação está em acordo com guias de tratamento já existentes (por exemplo, o European Dermatology Forum e a American Academy of Dermatology), que declaram que tratamentos imunossupressores são contraindicados em pacientes com infecções ativas.